Geron Co. (NASDAQ:GERN – Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 66,350,000 shares, a decrease of 5.4% from the November 15th total of 70,130,000 shares. Based on an average trading volume of 8,070,000 shares, the days-to-cover ratio is presently 8.2 days.
Analyst Ratings Changes
Several brokerages recently issued reports on GERN. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Geron in a research report on Tuesday, December 10th. Scotiabank began coverage on shares of Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price objective for the company. Barclays raised shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. Leerink Partnrs raised Geron to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Leerink Partners started coverage on Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron currently has a consensus rating of “Moderate Buy” and an average price target of $7.15.
View Our Latest Report on GERN
Hedge Funds Weigh In On Geron
Geron Trading Down 1.3 %
Shares of Geron stock opened at $3.81 on Tuesday. The stock has a market cap of $2.30 billion, a P/E ratio of -11.91 and a beta of 0.51. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The business’s 50 day moving average is $4.06 and its 200-day moving average is $4.36.
Geron (NASDAQ:GERN – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The firm had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company’s revenue for the quarter was up 17138.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.08) earnings per share. Equities research analysts predict that Geron will post -0.25 earnings per share for the current fiscal year.
Geron Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Articles
- Five stocks we like better than Geron
- Comparing and Trading High PE Ratio Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- What is the Australian Securities Exchange (ASX)
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.